Researchers have found that CDK4/6 inhibitors not only suppress cell proliferation and trigger anti-tumor immune responses(Deng et al. 2018; Goel et al. 2017; Zhang et al. 2018), but also inhibit tumor growth through mechanisms including regulating mitotic kinase signaling, inducing senescent-like phenotypes(Wang et al. 2022), and enhancing the immunogenicity of cancer cells(Goel et al. 2018). The gene discussed is CDK4; the disease is cancer.